Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
| |
| 2 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| recombinant human erythropoietin | Drug | 36000IU（0.5mL）s.c./week for 8 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| The increase in Hb concentration | week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in QOL scores | 8 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yoshiharu Ishikura | Chugai Pharmaceutical | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| recombinant human erythropoietin placebo |
| Drug |
0 IU(0.5mL)s.c./week for 8 weeks |
|